Roedl, Kevin http://orcid.org/0000-0002-0721-9027
De Rosa, Silvia
Fischer, Marlene
Braunsteiner, Josephine
Schmidt-Lauber, Christian
Jarczak, Dominik
Huber, Tobias B.
Kluge, Stefan
Wichmann, Dominic
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 7 April 2023
Accepted: 12 October 2023
First Online: 24 November 2023
Declarations
:
: The study was approved by the local clinical institutional review board and complies with the Declaration of Helsinki. The study was registered with the Ethics Committee of the Hamburg Chamber of Physicians (No.: 2021-300112-WF). Owing to the retrospective character of the study and its anonymized data collection, the need for informed consent was waived.
: Not applicable.
: SDH, JB, DJ, CSL, TBH, MF do not report any conflicts of interest related to this article. SK received research support from Cytosorbents and Daiichi Sankyo. He also received lecture fees from ADVITOS, Biotest, Daiichi Sankyo, Fresenius Medical Care, Gilead, Mitsubishi Tanabe Pharma, MSD, Pfizer and Zoll. He received consultant fees from Fresenius, Gilead, MSD and Pfizer. DW received lecture honorarium from 3M, ADVANZ, AMEOS, Gilead, InfectoPharm, Kite, Lilly, MSD, Pfizer and Shionogi and consultation honorarium from Eumedica, EUSA-Pharm, Gilead, Kite, MSD, Novartis, Pfizer and Shionogi. No other potential conflict of interest relevant to this article was reported. KR received travel reimbursement from Gilead within the last 5 years.